RESUMEN
A background survey of UK breast radiotherapy techniques was performed prior to the introduction of the quality assurance programme for the Standardization of Radiotherapy (START) trial in breast cancer, a UK multicentre randomized trial of different dose fractionations for breast radiotherapy. Analysis of patient treatment plans was performed at this initial stage of the quality assurance programme to ensure eventual uniformity of treatment within the randomized trial and hence ensure reliable end results. As an integral part of this initial survey, three patient outlines of different size and shape were circulated between November 1997 and January 1998 to 56 UK radiotherapy centres. Dose distributions were produced according to the routine planning protocol of each department to provide information on treatment planning techniques. Criteria used for treatment plan production and the resultant dose distributions were analysed. The dose distributions varied between centres. Dose inhomogeneity of no more than 10% was achieved, on the central axis, for all chest wall and medium breast size plans. The number of larger breast size distributions exceeding a 10% dose gradient across the treatment volume was 54% (26). Most centres in the UK determine the breast dose distribution by planning on a two-dimensional contour taken along the central plane of the breast. Variation in the breast contour either side of this central plane is not taken into account. Care with plan optimization by selecting the most appropriate beam parameters can lead to an improvement in breast dosimetry.
Asunto(s)
Neoplasias de la Mama/radioterapia , Garantía de la Calidad de Atención de Salud/métodos , Planificación de la Radioterapia Asistida por Computador/normas , Femenino , Encuestas de Atención de la Salud , Humanos , Dosificación Radioterapéutica/normas , Ensayos Clínicos Controlados Aleatorios como Asunto , Reino UnidoRESUMEN
Pentoxifylline (oxpentifylline) is a methylxanthine derivative with potent hemorrheologic properties. In the United States it is marketed for the treatment of intermittent claudication. Human and animal studies have shown that pentoxifylline therapy results in a variety of physiological changes at the cellular level, which may be important in treating a diverse group of human afflictions. Immune modulation includes increased leukocyte deformability and chemotaxis, decreased endothelial leukocyte adhesion, decreased neutrophil degranulation and release of superoxides, decreased production of monocyte-derived tumor necrosis factor, decreased leukocyte responsiveness to interleukin 1 and tumor necrosis factor, inhibition of T and B lymphocyte activation, and decreased natural killer cell activity. Hypercoagulable states improve through decreased platelet aggregation and adhesion, increased plasminogen activator, increased plasmin, increased antithrombin III, decreased fibrinogen, decreased alpha 2-antiplasmin, decreased alpha 1-antitrypsin, and decreased alpha 2-macroglobulin. Wound healing and connective tissue disorders may respond to an increase in fibroblast collagenases and decreased collagen, fibronectin, and glycosaminoglycan production. Fibroblast responsiveness to tumor necrosis factor is also diminished. Potential medical uses of pentoxifylline are reviewed.